title: Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes.
abstract: Although diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, it is both clinically and morphologically heterogenous. The present study investigates the significance of survivin and a novel monoclonal antibody (MAb), T332, immunohistochemically for predicting the prognoses of DLBCL and its subtypes classified as germinal center B-cell-like type (GCB) and non-GCB type (NGCB) based on the expression profiles of CD10, bcl-6, and MUM1. A total of 60 cases of DLBCL (GCB, n = 22; NGCB, n = 38) were examined for the expression of survivin and T332 antigen. Survivin(+) DLBCL had a significantly worse prognosis (P = 0.01) than survivin(-) cases, as already reported, while survivin(+) GCB or NGCB tended to have poor prognoses (P = 0.06 and 0.07, respectively). However, T332(+) DLBCL and NGCB had significantly more unfavorable prognoses than T332(-) cases (P = 0.01 and 0.02, respectively) while there was no significant survival difference between the T332(+) and T332(-) groups of GCB (P = 0.11). Interestingly DLBCL coexpressing survivin and T332 (n = 13) had a significantly worse prognosis (P = 0.009) than the remaining single positive and double negative cases (n = 31). In conclusion, survivin and the novel MAb, T332, might be a good predictor of DLBCL and its subtypes.
authors.affiliation: Department of Immunopathology, Gifu University Graduate School of Medicine, Gifu, Japan. miyauchi@cc.gifu-u.ac.jp
authors.forename: Rumiko
authors.initials: R
authors.lastname: Watanuki-Miyauchi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Kojima
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hara
authors.forename: Naoe
authors.initials: N
authors.lastname: Goto
authors.forename: Seiji
authors.initials: S
authors.lastname: Kasahara
authors.forename: Masanao
authors.initials: M
authors.lastname: Saio
authors.forename: Hisataka
authors.initials: H
authors.lastname: Moriwaki
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takami
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000276:immunology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins; D016393:Lymphoma, B-Cell / Q000378:metabolism / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism / Q000473:pathology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D009363:Neoplasm Proteins; D011379:Prognosis; D016019:Survival Analysis; D000077022:Survivin
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin